Research in Focus
Your support is so important
Sadly, blood cancer is one of the most common, costly and fatal cancers in Australia. There are currently no screening programs and there’s no way to prevent blood cancer.
While these numbers tell a staggering tale, it’s the real-life nightmare faced by families every day that means we cannot, and will not, rest.
Deanne lost her 13-year-old son Jacob to blood cancer and recalls the way he shared with his three siblings the news that there were no treatment options left.
“Jacob’s the youngest and he sat them all down, put his arms around them said, ‘my leukaemia’s back and I’m going to die. But it’s okay, we’re not going to stop fighting’.”
“I miss him every day and am dedicated to making sure he is never forgotten. This is the greatest fear for every parent who has lost a child. He will always be my ‘almost’ 14-year old, and not a day goes by that I don’t think about my cheeky and mischievous boy watching over us.”
Your donations in action
Your generosity is working hard to drive better outcomes for Australians with blood cancer.
Investing in the researchers of tomorrow, today
Funding our country’s early career researchers will bring tomorrow’s breakthroughs sooner.
Excitingly, two of Australia’s promising researchers have been awarded Leukaemia Foundation and Haematology Society of Australia and New Zealand (HSANZ) PhD scholarships this year.
Thanks to the generosity of wonderful supporters like you, the research of Basit Salik and Dr Julian Grabek is working to improve the understanding and treatment for types of blood cancer called acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN).
Their focus on the biology of blood cancer means your support is fuelling high-impact and innovative research – research that may help change the way some blood cancers are diagnosed and treated.
“I’m so grateful for your support. It’s powerful to think that together, supporter and researcher, we can work to improve outcomes for Australians with MPN.”
– Dr Julian Grabek